ACP3 and posterior cortical atrophy: The first approved immunotherapy for PCa, sipuleucel-T, involves infusion of a patient’s autologous DC that have been pre-loaded with a recombinant fusion protein consisting of a known prostate TAA, prostatic acid phosphatase (PAP), fused with granulocyte-macrophage colony-stimulating factor (GM-CSF).